Bruno Chauffert

23.3k total citations · 7 hit papers
232 papers, 15.0k citations indexed

About

Bruno Chauffert is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bruno Chauffert has authored 232 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 69 papers in Pulmonary and Respiratory Medicine and 52 papers in Molecular Biology. Recurrent topics in Bruno Chauffert's work include Intraperitoneal and Appendiceal Malignancies (26 papers), Hepatocellular Carcinoma Treatment and Prognosis (23 papers) and Colorectal Cancer Treatments and Studies (21 papers). Bruno Chauffert is often cited by papers focused on Intraperitoneal and Appendiceal Malignancies (26 papers), Hepatocellular Carcinoma Treatment and Prognosis (23 papers) and Colorectal Cancer Treatments and Studies (21 papers). Bruno Chauffert collaborates with scholars based in France, United States and Switzerland. Bruno Chauffert's co-authors include François Ghiringhelli, Éric Solary, François Martin, Olivier Bouché, Marc Ychou, Thierry Conroy, Michel Ducreux, C. Montoto-Grillot, Pierre Michel and Jean‐Luc Raoul and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Bruno Chauffert

226 papers receiving 14.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

2011 5.5k citations Thierry Conroy, Olivier Bouché et al. profile →
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

2006 968 citations François Ghiringhelli, Sylvain Ladoire et al. profile →
CD4⁺CD25⁺ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative

2004 706 citations François Ghiringhelli, Nicolas Larmonier et al. profile →
Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4 + CD25 + regulatory T cell proliferation

2005 588 citations François Ghiringhelli, S. Roux et al. The Journal of Experimental Medicine profile →
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

2008 501 citations Bruno Chauffert, F. Mornex et al. Annals of Oncology profile →
Iron‐dependent cell death of hepatocellular carcinoma cells exposed to sorafenib

2013 474 citations Bruno Chauffert, Antoine Galmiche et al. profile →
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells

2014 315 citations Denis Chatelain, Bruno Chauffert et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Bruno Chauffert	9.3k	4.0k	3.9k	3.6k	2.9k	232	15.0k
Huamin Wang	11.5k 1.2×	5.6k 1.4×	4.0k 1.0×	4.5k 1.2×	2.0k 0.7×	256	17.9k
Emilio Bajetta	10.4k 1.1×	3.9k 1.0×	5.8k 1.5×	3.7k 1.0×	1.2k 0.4×	325	16.6k
Kosei Hirakawa	7.6k 0.8×	4.6k 1.2×	3.3k 0.9×	3.2k 0.9×	1.7k 0.6×	590	14.2k
Ramesh K. Ramanathan	10.2k 1.1×	3.9k 1.0×	4.0k 1.0×	2.3k 0.6×	1.1k 0.4×	316	15.9k
Geoffrey R. Weiss	8.2k 0.9×	4.2k 1.1×	4.6k 1.2×	1.5k 0.4×	2.5k 0.9×	194	13.1k
Joseph P. Eder	8.2k 0.9×	3.4k 0.9×	3.2k 0.8×	1.6k 0.4×	2.9k 1.0×	178	12.2k
Hedy L. Kindler	8.4k 0.9×	3.6k 0.9×	7.3k 1.9×	3.1k 0.8×	997 0.3×	400	16.1k
Alexandra Giatromanolaki	4.2k 0.5×	7.6k 1.9×	2.8k 0.7×	5.9k 1.6×	2.0k 0.7×	389	15.3k
Mace L. Rothenberg	10.9k 1.2×	4.9k 1.2×	3.5k 0.9×	3.4k 0.9×	619 0.2×	167	15.2k
Donato Nitti	5.9k 0.6×	3.3k 0.8×	3.3k 0.8×	2.6k 0.7×	1.8k 0.6×	326	13.7k

Countries citing papers authored by Bruno Chauffert

Since Specialization

Citations

This map shows the geographic impact of Bruno Chauffert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruno Chauffert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruno Chauffert more than expected).

Fields of papers citing papers by Bruno Chauffert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruno Chauffert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruno Chauffert. The network helps show where Bruno Chauffert may publish in the future.

Co-authorship network of co-authors of Bruno Chauffert

This figure shows the co-authorship network connecting the top 25 collaborators of Bruno Chauffert. A scholar is included among the top collaborators of Bruno Chauffert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruno Chauffert. Bruno Chauffert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Étienne-Selloum, Nelly, Mathieu Boone, Henri Sevestre, et al.. (2021). Expression Analysis of α5 Integrin Subunit Reveals Its Upregulation as a Negative Prognostic Biomarker for Glioblastoma. Pharmaceuticals. 14(9). 882–882. 5 indexed citations

Luporsi, Élisabeth, et al.. (2021). Iron deficiency in patients with cancer: a prospective cross-sectional study. BMJ Supportive & Palliative Care. 14(2). 215–221. 7 indexed citations

Turpin, Anthony, et al.. (2021). 69P Transferrin saturation shows high prevalence of iron deficiency in cancer patients under adjuvant and neo-adjuvant treatment. Annals of Oncology. 32. S385–S386. 1 indexed citations

Attencourt, Christophe, Alexandre Coutté, Mathieu Boone, et al.. (2018). Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma. BMC Cancer. 18(1). 964–964. 5 indexed citations

Sabbagh, Charles, Denis Chatelain, Christophe Attencourt, et al.. (2017). Impact of homogeneous pathologic response to preoperative chemotherapy in patients with multiple colorectal liver metastases. World Journal of Gastroenterology. 23(45). 8027–8034. 2 indexed citations

Dérangère, Valentin, et al.. (2016). PD-L1 and IL17 expression in tumor infiltrating lymphocytes are opposite prognostic factors in glioblastoma. Annals of Oncology. 27. vi104–vi104. 2 indexed citations

Sabbagh, Charles, Cyril Cossé, Bruno Chauffert, et al.. (2015). Oncological strategies for middle and low rectal cancer with synchronous liver metastases. International Journal of Surgery. 23(Pt A). 186–193. 9 indexed citations

Chauffert, Bruno, L. Feuvret, Franck Bonnetain, et al.. (2014). Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF. Annals of Oncology. 25(7). 1442–1447. 69 indexed citations

Facy, Olivier, Guy Magnin, Sylvain Ladoire, et al.. (2014). High pressure does not counterbalance the advantages of open techniques over closed techniques during heated intraperitoneal chemotherapy with oxaliplatin. Surgery. 157(1). 72–78. 22 indexed citations

10.

Chauffert, Bruno, et al.. (2013). Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma. Clinics and Research in Hepatology and Gastroenterology. 37(6). 614–618. 9 indexed citations

11.

Malka, David, Valérie Boige, Nathalie Jacques, et al.. (2011). Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Annals of Oncology. 23(4). 919–927. 39 indexed citations

12.

Boulin, Mathieu, Séverine Guiu, Bruno Chauffert, et al.. (2011). Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma. Anti-Cancer Drugs. 22(8). 741–748. 64 indexed citations

13.

Ladoire, Sylvain, Laurent Arnould, Grégoire Mignot, et al.. (2010). Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 125(1). 65–72. 110 indexed citations

14.

Ghiringhelli, François, Boris Guiu, Bruno Chauffert, & Sylvain Ladoire. (2009). Sirolimus, bevacizumab, 5-Fluorouracil and irinotecan for advanced colorectal cancer: A pilot study. World Journal of Gastroenterology. 15(34). 4278–4278. 6 indexed citations

15.

Chauffert, Bruno, F. Mornex, P. Rougier, et al.. (2008). Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Annals of Oncology. 19(9). 1592–1599. 501 indexed citations breakdown →

16.

Magnin, Guy, Philippe Moretto, M.D. Ynsa, et al.. (2006). High Intra-abdominal Pressure Enhances the Penetration and Antitumor Effect of Intraperitoneal Cisplatin on Experimental Peritoneal Carcinomatosis. Annals of Surgery. 244(1). 106–112. 134 indexed citations

17.

Ghiringhelli, François, S. Roux, Arnaud Parcellier, et al.. (2005). Tumor cells convert immature myeloid dendritic cells into TGF-β–secreting cells inducing CD4 + CD25 + regulatory T cell proliferation. The Journal of Experimental Medicine. 202(7). 919–929. 588 indexed citations breakdown →

18.

Bonnotte, Bernard, Nicolas Larmonier, Nathalie Favre, et al.. (2001). Identification of Tumor-Infiltrating Macrophages as the Killers of Tumor Cells After Immunization in a Rat Model System. The Journal of Immunology. 167(9). 5077–5083. 61 indexed citations

19.

Garrido, Carmen, Annie Fromentin, Arlette Hammann, et al.. (1997). HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs.. PubMed. 57(13). 2661–7. 208 indexed citations

20.

Pelletier, H, J Millot, Bruno Chauffert, et al.. (1990). Mechanisms of resistance of confluent human and rat colon cancer cells to anthracyclines: alteration of drug passive diffusion.. PubMed. 50(20). 6626–31. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact